Coronavirus disease 2019 (COVID-19) is associated with systemic
inflammation. A wide range of
adipokines activities suggests they influence pathogenesis and
infection course. The aim was to assess concentrations of chemerin, omentin, and vaspin among
COVID-19 patients with an emphasis on
adipokines relationship with
COVID-19 severity, concomitant metabolic abnormalities and
liver dysfunction. Serum chemerin, omentin and vaspin concentrations were measured in serum collected from 70
COVID-19 patients at the moment of admission to hospital, before any treatment was applied and 20 healthy controls. Serum chemerin and omentin concentrations were significantly decreased in
COVID-19 patients compared to healthy volunteers (271.0 vs. 373.0 ng/ml; p < 0.001 and 482.1 vs. 814.3 ng/ml; p = 0.01, respectively). There were no correlations of analyzed
adipokines with
COVID-19 severity based on the presence of
pneumonia,
dyspnea, or necessity of Intensive Care Unit hospitalization (ICU). Liver test abnormalities did not influence
adipokines levels. Elevated GGT activity was associated with ICU admission, presence of
pneumonia and elevated concentrations of CRP,
ferritin and
interleukin 6. Chemerin and omentin depletion in
COVID-19 patients suggests that this
adipokines deficiency play influential role in disease pathogenesis. However, there was no relationship between lower
adipokines level and frequency of
COVID-19 symptoms as well as disease severity. The only predictive factor which could predispose to a more severe
COVID-19 course, including the presence of
pneumonia and ICU hospitalization, was GGT activity.